Navigation Links
Intestinal enzyme helps maintain population of beneficial bacteria

An enzyme that keeps intestinal bacteria out of the bloodstream may also play an important role in maintaining the normal microbial population of the gastrointestinal system. Since the loss of beneficial bacteria that usually results from antibiotic therapy can sometimes lead to serious health problems, a treatment that maintains microbial levels could have significant benefits.

"Our mouse studies confirmed that giving this enzyme by mouth keeps the gut healthy, in terms of the microbes that usually live there," says Richard Hodin, MD, of the Massachusetts General Hospital (MGH) Department of Surgery, senior author of the report in the November issue of the journal Gut. "This could prevent infection with dangerous bacteria like Salmonella and C. difficile, which can occur when the normal bacterial population becomes depleted, and may lead to development of a supplement to maintain intestinal health whenever someone takes an antibiotic."

Virtually all higher animals maintain a population of microbes primarily bacteria in their digestive tracts. These organisms are not only harmless, they also benefit their host by helping with digestion, and their presence prevents the more pathogenic bacteria that may be present from proliferating. Because antibiotics kill all non-resistant bacteria, including those residing in the intestines, the usual balance of beneficial versus harmful microbes is destroyed, leading to problems ranging from diarrhea to infections with dangerous antibiotic-resistant organisms.

A 2008 study by members of Hodin's team that investigated why intestinal bacteria and their toxins do not pass into the bloodstream found that intestinal alkaline phosphatase (IAP), an enzyme produced by the intestinal lining, blocks the activity of a toxic molecule found on many pathogenic bacteria. Because that study and findings by other groups showed that IAP acts against several bacterial toxins, the MGH researchers looked at whether the enzyme directly interacted with intestinal bacteria.

Studies of mice lacking the gene for IAP revealed that the animals had reduced levels of all intestinal bacteria and practically none of the common beneficial strains of E. coli. In fact, the most common E. coli strain would not grow if introduced into these knockout mice. But when the animals received oral doses of IAP, beneficial E. coli proliferated quickly after other microbial species were killed by antibiotics. Experiments with normal mice infected with an antibiotic-resistant Salmonella strain showed that IAP treatment significantly reduced Salmonella levels in the animals' feces. Although only 20 percent of animals not treated with IAP survived, 70 percent of those receiving the enzyme were alive 7 days later.

"We believe that IAP rapidly restores E. coli and other beneficial bacteria after antibiotic treatment and that the higher numbers of these bacteria prevent colonization by Salmonella or other pathogens by competing for nutrients and attachment sites," says Mahdu Malo, PhD, MBBS, of MGH Surgery, corresponding and first author of the Gut paper. "We need to test this approach in larger animals before planning a human clinical trial, but this approach has the potential of solving a common, often serious health problem."


Contact: Sue McGreevey
Massachusetts General Hospital

Related medicine news :

1. Protein Appears Key to Intestinal Balance
2. ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
3. Feedback loop explains inflammatory effect on intestinal lining
4. A new endoscopic technique for gastrointestinal perforations: the over-the-scope-clip
5. Factors increasing the risk of atrophic gastritis and intestinal metaplasia
6. The effect of dietary supplements, acids and animal protein on gastrointestinal disorders
7. Suppressing activity of common intestinal bacteria reduces tumor growth
8. Motorcycle Cancer Risk and ELF EMF Radiation Invasion of Gastrointestinal Melatonin
9. What affects the gastrointestinal symptoms in peritoneal dialysis patients?
10. Optimal surgical procedure for duodenal gastrointestinal stromal tumors
11. New studies highlight obesitys impact on gastrointestinal health
Post Your Comments:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... , ... June 27, 2016 , ... recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology: